Ser18

Site Information
ALtGsQssHAsLRNI SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 14581172

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 4 , 5 , 6 )
Disease tissue studied:	leukemia ( 4 ) , acute myelogenous leukemia ( 4 ) , melanoma skin cancer ( 1 )
Relevant cell line - cell type - tissue:	A498 (renal) ( 5 ) , HeLa (cervical) ( 6 ) , Jurkat (T lymphocyte) ( 2 ) , KG-1 (myeloid) ( 4 ) , WM239A (melanocyte) ( 1 )

References
1	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
2	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
3	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
4	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
5	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
6	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info